Updates are available Correction dated 2023-07-27
Click to view Correction: https://doi.org/10.1038/s41434-023-00412-2
-
Authors
Gilkes, Janine A.
Judkins, Benjamin L. http://orcid.org/0000-0002-1119-116X
Herrera, Brontie N.
Mandel, Ronald J.
Boye, Sanford L.
Boye, Shannon E.
Srivastava, Arun
Heldermon, Coy D. http://orcid.org/0000-0002-2148-2868
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL-097088)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM-119186)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R21 EB-015684)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS102624)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (K085141)
Gatorade Trust through funds distributed by the University of Florida Foundation Fighting Blindness
- License Information
-
More Information
Article History
Received: 2 April 2020
Revised: 3 September 2020
Accepted: 19 October 2020
First Online: 26 November 2020
Change Date: 27 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41434-023-00412-2
Compliance with ethical standards
:
: CDH, RJM, and AS declare stock ownership and co-founding of Lacerta Therapeutics, which develops gene therapy for CNS diseases. AS also holds several issued US Patents on AAV vectors that have been licensed to various gene therapy companies, and is a co-founder of Nirvana Therapeutics. SEB and SLB declare stock ownership and co-founding of Atsena Therapeutics, which develops gene therapies for ocular diseases.
